Farnesoid X receptor represses hepatic human APOA gene expression indumathi chennamsetty

Journal of Clinical Investigation

Volumn 121, Issue 9, 2011, Pages 3724-3734

  Chennamsetty, Indumathi ^a   Claudel, Thierry ^a   Kostner, Karam M ^a,b   Baghdasaryan, Anna ^a   Kratky, Dagmar ^a   Levak Frank, Sanja ^a   Frank, Sasa ^a   Gonzalez, Frank J ^c   Trauner, Michael ^a,d   Kostner, Gert M ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NATIONAL CANCER INSTITUTE   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; BILE ACID; CHOLIC ACID; FARNESOID X RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; LIPOPROTEIN A; NUCLEOTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILE DUCT OBSTRUCTION; BINDING AFFINITY; BLOOD LEVEL; CHOLESTASIS; CLINICAL ARTICLE; COMMON BILE DUCT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS A; BILE ACIDS AND SALTS; CELLS, CULTURED; FEMALE; GENE EXPRESSION; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; JAUNDICE, OBSTRUCTIVE; LIVER; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; RANDOM ALLOCATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 80052380574     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45277     Document Type: Article

References (66)

1. Hobbs H.H., White A.L. Lipoprotein(a): Intrigues and insights. Curr Opin Lipidol. 1999;10(3):225-236. (Pubitemid 29405913)
2. Kostner K.M., Kostner G.M. Lipoprotein(a): Still an enigma? Curr Opin Lipidol. 2002;13(4):391-396. (Pubitemid 34831942)
3. Gaubatz J.W., Heideman C., Gotto A.M. Jr, Morrisett J.D., Dahlen G.H. Human plasma lipoprotein [a]. Structural properties. J Biol Chem. 1983;258(7):4582-4589. (Pubitemid 13080684)
4. Kostner G.M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Qunici G.B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38(1-2):51-61. (Pubitemid 11138606)
5. Rhoads G.G., Dahlen G., Berg K., Morton N.E., Dannenberg A.L. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256(18):2540-2544. (Pubitemid 17025291)
6. Srinivasan S.R., Dahlen G.H., Jarpa R.A., Webber L.S., Berenson G.S. Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation. 1991;84(1):160-167.
7. Tregouet D.A., et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41(3):283-285.
8. Clarke R., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-2528.
9. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331-2339.
10. Erqou S., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160-2167.
11. Lanktree M.B., Anand S.S., Yusuf S., Hegele R.A. Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet. 2010;3(1):39-46.
12. Nordestgaard B.G., et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J. 2010;31(23):2844-2853.
13. Lawn R.M., Wade D.P., Hammer R.E., Chiesa G., Verstuyft J.G., Rubin E.M. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 1992;360(6405):670-672. (Pubitemid 23007679)
14. Callow M.J., Verstuyft J., Tangirala R., Palinski W., Rubin E.M. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest. 1995;96(3):1639-1646.
15. Rouy D., Grailhe P., Nigon F., Chapman J., Angles- Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb. 1991;11(3):629-638.
16. Kostner K.M., Kostner G.M. Therapy of hyper-Lp(a). Handb Exp Pharmacol. 2005;170(170):519-536.
17. Krempler F., Kostner G.M., Bolzano K., Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest. 1980;65(6):1483-1490. (Pubitemid 10122391)
18. Rader D.J., et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93(6):2758-2763.
19. Frank S., Gauster M., Strauss J., Hrzenjak A., Kostner G.M. Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo. Gene Ther. 2001;8(6):425-430. (Pubitemid 32266397)
20. Parks D.J., et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science. 1999; 284(5418):1365-1368. (Pubitemid 29289664)
21. Forman B.M., et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995;81(5):687-693.
22. Makishima M., et al. Identif ication of a nuclear receptor for bile acids. Science. 1999; 284(5418):1362-1365. (Pubitemid 29289663)
23. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell. 1999; 3(5):543-553. (Pubitemid 29268438)
24. Laffitte B.A., Kast H.R., Nguyen C.M., Zavacki A.M., Moore D.D., Edwards P.A. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem. 2000; 275(14):10638-10647. (Pubitemid 30202131)
25. Barbier O., et al. FXR induces the UGT2B4 enzyme in hepatocytes: A potential mechanism of negative feedback control of FXR activity. Gastroenterology. 2003;124(7):1926-1940. (Pubitemid 36666787)
26. Lu Y., Heydel J.M., Li X., Bratton S., Lindblom T., Radominska-Pandya A. Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: A potential role for a negative farnesoid X receptor response element. Drug Metab Dispos. 2005;33(7):937-946. (Pubitemid 41002775)
27. Claudel T., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest. 2002;109(7):961-971. (Pubitemid 34275117)
28. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731-744.
29. Kim I., et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007;48(12):2664-2672.
30. del Castillo-Olivares A, Gil G. Suppression of sterol 12alpha-hydroxylase transcription by the short heterodimer partner: insights into the repression mechanism. Nucleic Acids Res. 2001; 29(19):4035-4042.
31. Goodwin B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell. 2000;6(3):517-526.
32. Lu T.T., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6(3):507-515.
33. Brendel C., Schoonjans K., Botrugno O.A., Treuter E., Auwerx J. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol. 2002; 16(9):2065-2076. (Pubitemid 35013455)
34. Inagaki T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005;2(4):217-225.
35. Schuetz E.G., et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem. 2001;276(42):39411-39418. (Pubitemid 37371319)
36. Zollner G., et al. Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney, and intestine. J Hepatol. 2003;39(4):480-488. (Pubitemid 37204645)
37. Davis R.A., Miyake J.H., Hui T.Y., Spann N.J. Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J Lipid Res. 2002;43(4):533-543. (Pubitemid 34252327)
38. Claudel T., Zollner G., Wagner M., Trauner M. Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis and gallstone disease [published online ahead of print December 29, 2010]. Biochim Biophys Acta. 2011;1812(8):867-878.
39. Staudinger J.L., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001;98(6):3369-3374. (Pubitemid 32220852)
40. Gupta S., Stravitz R.T., Dent P., Hylemon P.B. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem. 2001; 276(19):15816-15822.
41. Cartharius K., et al. MatInspector and beyond: Promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21(13):2933-2942. (Pubitemid 40916416)
42. Podvinec M., Kaufmann M.R., Handschin C., Meyer U.A. NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol Endocrinol. 2002;16(6):1269-1279. (Pubitemid 34621075)
43. Claudel T., et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003;125(2):544-555. (Pubitemid 36929436)
44. Anisfeld A.M., et al. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J Biol Chem. 2003;278(22):20420-20428. (Pubitemid 36799244)
45. Fraser J.D., Martinez V., Straney R., Briggs M.R. DNA binding and transcription activation specificity of hepatocyte nuclear factor 4. Nucleic Acids Res. 1998; 26(11):2702-2707. (Pubitemid 28297385)
46. Nicholls S.J., et al. Lipoprotein(a) levels and longterm cardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010;51(10):3055-3061.
47. Miyazaki-Anzai S., Levi M., Kratzer A., Ting T.C., Lewis L.B., Miyazaki M. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. Circ Res. 2010;106(12):1807-1817.
48. Evans M.J., et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009;296(3):G543-G552.
49. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-364.
50. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251(3):365-374.
51. Hixson J.E., Jett C., Birnbaum S. Identification of promoter sequences in the 5′ untranslated region of the baboon apolipoprotein[a] gene. J Lipid Res. 1996;37(11):2324-2331.
52. Puckey L.H., Knight B.L. Sequence and functional changes in a putative enhancer region upstream of the apolipoprotein(a) gene. Atherosclerosis. 2003;166(1):119-127. (Pubitemid 35449607)
53. Chong H.K., et al. Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1. Nucleic Acids Res. 2010;38(18):6007-6017.
54. Hayhurst G.P., Lee Y.H., Lambert G., Ward J.M., Gonzalez F.J. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 2001;21(4):1393-1403. (Pubitemid 32114986)
55. Holt J.A., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17(13):1581-1591. (Pubitemid 36828786)
56. Seol W., Choi H.S., Moore D.D. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science. 1996;272(5266):1336-1339. (Pubitemid 26199974)
57. Mataki C., et al. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol Cell Biol. 2007;27(23):8330-8339. (Pubitemid 350234244)
58. Lee Y.K., et al. Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol Endocrinol. 2008;22(6):1345-1356.
59. Kostner G.M., Ibovnik A., Holzer H., Grillhofer H. Preparation of a stable fresh frozen primary lipoprotein[a] (Lp[a]) standard. J Lipid Res. 1999; 40(12):2255-2263. (Pubitemid 30017527)
60. Kraft H.G., Lingenhel A., Bader G., Kostner G.M., Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: Proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis. 1996;125(1):53-61. (Pubitemid 26267122)
61. Bos E.S., Van der Doelen A.A., Denissen A.E., Goverde B.C., Magnani H.N., Kostner G.M. A novel assay for the quantitative determination of lipoprotein-X (LP-X) in serum. Clin Chim Acta. 1983;127(3):383-390. (Pubitemid 13190185)
62. Mashige F., Imai K., Osuga T. A simple and sensitive assay of total serum bile acids. Clin Chim Acta. 1976;70(1):79-86.
63. Frazer K.A., Narla G., Zhang J.L., Rubin E.M. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet. 1995;9(4):424-431.
64. Wagner M., et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology. 2003;125(3):825-838. (Pubitemid 37070700)
65. Salonpaa P., Pelkonen O., Kojo A., Pasanen M., Negishi M., Raunio H. Cytochrome P4502A5 expression and inducibility by phenobarbital is modulated by cAMP in mouse primary hepatocytes. Biochem Biophys Res Commun. 1994;205(1):631-637. (Pubitemid 24381673)
66. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):e36.